Upstream Bio, Inc. (UPB)
2.74
-0.25
(-8.36%)
USD |
NASDAQ |
Oct 23, 16:00
2.735
0.00 (0.00%)
After-Hours: 20:00
Upstream Bio EPS Diluted (Quarterly) : -0.7276 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7276 |
| March 31, 2026 | -0.7471 |
| December 31, 2025 | -0.7857 |
| September 30, 2025 | -0.6258 |
| Date | Value |
|---|---|
| June 30, 2025 | -0.7433 |
| March 31, 2025 | -0.5084 |
| December 31, 2024 | -0.4065 |
| September 30, 2024 | -0.3924 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Sutro Biopharma, Inc. | -2.325 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -39.70M |
| Revenue (Quarterly) | 0.773M |
| Total Expenses (Quarterly) | 40.48M |
| Enterprise Value | -110.28M |
| Gross Profit Margin (Quarterly) | 93.53% |
| Profit Margin (Quarterly) | -5.14K% |
| Earnings Yield | -105.3% |
| Normalized Earnings Yield | -105.23 |